KRW 1446.0
(-0.69%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 2.6 Billion KRW | 1.6% |
2022 | 2.55 Billion KRW | -16.0% |
2021 | 3.04 Billion KRW | 93.83% |
2020 | 1.57 Billion KRW | 1050.64% |
2019 | 136.61 Million KRW | -45.86% |
2018 | 252.32 Million KRW | 3648.59% |
2017 | 6.73 Million KRW | -98.85% |
2016 | 585.81 Million KRW | 1.39% |
2015 | 577.78 Million KRW | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 815.96 Million KRW | 41.23% |
2024 Q2 | 562.88 Million KRW | -31.02% |
2023 Q1 | 519.19 Million KRW | -23.35% |
2023 Q3 | 957.74 Million KRW | 75.53% |
2023 Q4 | 577.75 Million KRW | -39.68% |
2023 Q2 | 545.62 Million KRW | 5.09% |
2023 FY | 2.6 Billion KRW | 1.6% |
2022 Q2 | 535.2 Million KRW | -38.24% |
2022 FY | 2.55 Billion KRW | -16.0% |
2022 Q4 | 677.35 Million KRW | 41.03% |
2022 Q3 | 480.29 Million KRW | -10.26% |
2022 Q1 | 866.63 Million KRW | -46.15% |
2021 FY | 3.04 Billion KRW | 93.83% |
2021 Q2 | 298.69 Million KRW | -33.6% |
2021 Q3 | 689 Million KRW | 130.67% |
2021 Q4 | 1.6 Billion KRW | 133.59% |
2021 Q1 | 449.82 Million KRW | -35.35% |
2020 Q1 | 221.13 Million KRW | 468.45% |
2020 FY | 1.57 Billion KRW | 1050.64% |
2020 Q4 | 695.83 Million KRW | 197.48% |
2020 Q3 | 233.91 Million KRW | -44.45% |
2020 Q2 | 421.11 Million KRW | 90.44% |
2019 FY | 136.61 Million KRW | -45.86% |
2019 Q4 | -60.01 Million KRW | -132.03% |
2019 Q3 | 187.35 Million KRW | 0.0% |
2018 FY | 252.32 Million KRW | 3648.59% |
2017 FY | 6.73 Million KRW | -98.85% |
2016 FY | 585.81 Million KRW | 1.39% |
2015 FY | 577.78 Million KRW | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 355.84 Billion KRW | 99.269% |
InBody Co.,Ltd | 170.35 Billion KRW | 98.474% |
Curexo Inc. | 72.88 Billion KRW | 96.432% |
Seegene, Inc. | 367.37 Billion KRW | 99.292% |
i-SENS, Inc. | 265.12 Billion KRW | 99.019% |
Ray Co., Ltd. | 145.88 Billion KRW | 98.218% |
Sugentech Inc. | 7.13 Billion KRW | 63.542% |
L&C Bio Co., Ltd | 68.86 Billion KRW | 96.224% |